DOCSLIB.ORG

Phenyl Salicylate Structure Search

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phenyl Salicylate Structure Search Phenyl salicylate Structure Search ChemicalBook >> CAS DataBase List >>Phenyl salicylate Phenyl salicylate Description References CAS No. 118-55-8 Chemical Name: Phenyl salicylate Synonyms SALOL;Musol;FEMA 3960;Salphenyl;Seesorb 201;'LGC' (2613);'LGC' (2411);Phenyl salicy;Seesorb K 201;AURORA KA-3673 CBNumber: CB9322550 Molecular Formula: C13H10O3 Formula Weight: 214.22 Phenyl salicylate MOL File: 118-55-8.mol Request For Quotation Properties Safety Price 12 Uses Suppliers 232 Phenyl salicylate Properties Melting point: 41-43 °C(lit.) Boiling point: 172-173 °C12 mm Hg(lit.) Density 1.250g/cm3 FEMA 3960 | PHENYL SALICYLATE Flash point: >230 °F storage temp. room temp solubility dioxane: 0.1 g/mL, clear, colorless form Fine Crystalline Powder color White Water Solubility Soluble in alcohol, ether, chloroform, turpentine, acetone and benzene. Sparingly soluble in chloroformbenzene. Insoluble in water. Merck 14,7310 BRN 393969 Stability: Light sensitive. Incompatible with strong oxidants. Flammable. CAS DataBase Reference 118-55-8(CAS DataBase Reference) NIST Chemistry Reference Benzoic acid, 2-hydroxy-, phenyl ester(118-55-8) EPA Substance Registry Benzoic acid, 2-hydroxy-, phenyl ester(118-55-8) System SAFETY Risk and Safety Statements Hazard and Precautionary Statements (GHS) Symbol(GHS): Signal word: Warning Hazard statements: Signal Code Hazard statements Hazard class Category Pictogram P-Codes word May be harmfulif Category H303 Acute toxicity,oral P312 swallowed 5 Causes skin Category P264, P280, P302+P352, H315 Skin corrosion/irritation Warning irritation 2 P321,P332+P313, P362 Causes serious Category P264, P280, H319 Serious eye damage/eye irritation Warning eye irritation 2A P305+P351+P338,P337+P313P May cause Specific target organ toxicity, single Category H335 Warning respiratory irritation exposure;Respiratory tract irritation 3 Precautionary statements: P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P304+P340 IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. P305+P351+P338 Continuerinsing. P405 Store locked up. Phenyl salicylate price More Price(12) Manufacturer Product number Product description CAS number Packaging Price Updated Buy Sigma-Aldrich 149187 Phenyl salicylate 99% 118-55-8 50g $42.3 2017-11-08 Buy Sigma-Aldrich 149187 Phenyl salicylate 99% 118-55-8 250g $47.3 2017-11-08 Buy TCI Chemical S0017 Phenyl Salicylate >98.0%(GC) 118-55-8 25g $15 2017-12-01 Buy TCI Chemical S0017 Phenyl Salicylate >98.0%(GC) 118-55-8 500g $56 2017-12-01 Buy Alfa Aesar B20686 Phenyl salicylate, 99% 118-55-8 500g $70 2017-11-08 Buy Phenyl salicylate Chemical Properties,Uses,Production Description Phenyl salicylate (chemical formula: C13H10O3) belongs to the family of hydroxybenzoic acid which are compound containing a hydroxybenzoic acid or its derivative. It is manufactured through the chemical reaction between phenol and salicylic acid. Phenyl salicylate has several medical properties. It can be used as analgesic to relieve pain, as an antiseptic with antibacterial effect as well as a kind of antipyretic for the treatment of fever. It is also used for the treatment of inflammation triggered by the lower urinary tract. However, it is no longer commonly applied to human medicine, but is still used in veterinary medicine. References https://pubchem.ncbi.nlm.nih.gov/compound/Phenyl_salicylate#section=Top http://www.wisegeek.com/what-are-the-medical-uses-of-phenyl-salicylate.htm Chemical Properties white crystalline solid with an aromatic odour Definition ChEBI: A benzoate ester that is the phenyl ester of salicylic acid. Also known as salol, it can be formed by heating salicylic acid with phenol and is used in the manufacture of some polymers, lacquers, adhesives, waxes and polishes. Uses In the manufacture of various polymers for the plastics industry, also in lacquers, adhesives, waxes, polishes. In suntan oils and cremes. As light absorber to prevent discoloration of plastics. Has some plasticizer properties. General Description White crystals. Insoluble in water. Air & Water Reactions Insoluble in water. Reactivity Profile Incompatible with bromine water, ferric salts, camphor, phenol, chloral hydrate, monobrominated camphor, thymol, or urethane in trituration. Fire Hazard Flash point data for Phenyl salicylate are not available, however Phenyl salicylate is probably combustible. Phenyl salicylate Preparation Products And Raw materials Raw materials Salicylic acid Preparation Products 2-Hydroxy-N-(4-hydroxyphenyl)-benzamide Xanthone Salicylanilide Phenyl salicylate Suppliers Global( 232)Suppliers Austria 1 Supplier Tel Fax Email Country ProdList Advantage Abel@chem Shenzhen Sendi Biotechnology Co.Ltd. 0755-23311925 18102838259 0755-23311925 CHINA 3229 55 bj.com info@tianfuc Henan Tianfu Chemical Co.,Ltd. 0371-55170693 0371-55170693 CHINA 20810 55 hem.com 86-0551-65418684 189498237 info@tnjche Hefei TNJ Chemical Industry Co.,Ltd. 86-0551-65418684 China 1410 55 63 m.com market@riso HUBEI RISON CHEMICAL CO.,LTD 027 83642615 13995607107 027 83660699 China 292 58 nchem.com Hangzhou chemfluoro Chemical Co., Lt chemfluoro 0571-86780539 0571-86780539 China 24 58 d. @126.com jkinfo@jkche 400-666-7788 +86-10-828488 mical.com;m J & K SCIENTIFIC LTD. +86-10-82849933 China 96819 76 33 arket6@jkch emical.com +86-(0)21-61259100(Shanghai +86-(0)21-61259102(Shanghai Meryer (Shanghai) Chemical Technolo ) +86-(0)755-86170099(ShenZ ) +86-(0)755-86170066(ShenZ sh@meryer. China 40398 62 gy Co., Ltd. hen) +86-(0)10-62670440(Beiji hen) +86-(0)10-88580358(Beiji com ng) ng) saleschina Alfa Aesar 400-610-6006; 021-67582000 021-67582001/03/05 @alfa-asia.c China 30309 84 om sales@tcish TCI (Shanghai) Development Co., Ltd. 800-988-0390 021-67121385 anghai.com. China 22830 81 cn info@energy Energy Chemical 021-58432009 / 400-005-6266 021-58436166-800 -chemical.co China 44192 61 m 118-55-8(Phenyl salicylate)Related Search: BLUE DYE Phenyl salicylate Triphenyl phosphate Diphenyl ether Phenylacetic acid Dimethyl phthalate TRIS(TRIMETHYLSILYL) PHOSPHATE PHENETHYL SALICYLATE Triphenyl phosphite Sodium salicylate DISPERSE BLUE 102 Methyl acrylate PHENYL VALERATE Benzyl benzoate DISPERSE DYE Phenyl chloroformate Dimethyl succinate Isoamyl o-hydroxybenzoate Phenyl Esters (Liquid Crystals) Liquid Crystals & Related Compounds SALOL SALICYLIC ACID PHENYL ESTER PHENYL 2-HYDROXYBENZOATE PHENYL SALICYLATE PHENYL-O-HYDROXYBENZOATE O-HYDROXYBENZOIC ACID PHENYL ESTER Esters Organic Building Blocks 2-HYDROXYBENZOIC ACID PHENYL ESTER Building Blocks 118-55-8 Carbonyl Compounds C12 to C63 'LGC' (2411) 'LGC' (2613) LABOTEST-BB LT00053052 Disperse Dye Blue EXSF FEMA 3960 AURORA KA-3673 Phenyl Salicylate/Phenyl 2-hydroxybenzoate/Salol ACETATE PHENYL SALICYLATE 99+% Phenyl2-hydroxybenzoate=Salol PHENYLSALICYLATE,CRYSTAL,PURIFIED Phenylsalicylat C6H4OHCOOC6H5 HOC6H4COOC6H5 Aromatic Esters Phenyl 2-hydroxybenzoate(Phenyl salicylate) Functional Materials Liquid Crystals & Related Compounds Phenyl Esters (Liquid Crystals) 2HOC6H4CO2C6H5 Salicylic acid phenyl Phenyl salicy Phenyl salicylate,Salol Phenyl Salicylate, crystal Phenyl Salicylate Melting Point Standard (500 mg) (Approximately 41 degrees) Phenyl salicylate, 99% 250GR 204-259-2 2-Hydroxybenzoic Acid Phenyl Ester Phenyl 2-Hydroxybenzoate Salicylic Acid Phenyl Ester Building Blocks C12 to C63 Carbonyl Compounds Chemical Synthesis Esters Liquid Crystals Materials Science Organic and Printed Electronics Organic Building Blocks Phenyl salicylate, 2-(Phenoxycarbonyl)phenol, Salol Phenyl Salicytate Phenyl salicylate melting point standard Mettler-Toledo Calibration substance ME 30034252, Phenyl salicylate Phenyl salicylate ReagentPlus(R), 99% Phenyl salicylate Vetec(TM) reagent grade, 98% Copyright 2017 © ChemicalBook. All rights reserved.
Load more

Recommended publications
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • Additional Drug Coverage
    Additional Drug Coverage Additional prescription drug coverage Your plan includes extra coverage for certain drugs and supplies as shown below. This is not a complete list of prescription drugs and supplies covered by our plan. For a complete list, please call Customer Service toll-free at (866) 868-0609 (TTY: 711), 7 a.m. – 7 p.m. CT, Monday – Friday and 7 a.m. – 3 p.m. CT, Saturday. Lower-cost Medicare prescription drugs and supplies Your plan covers some of your Medicare prescription drugs and supplies at a $0 copay. If you have questions, call us toll-free at (866) 868-0609 (TTY: 711), 7 a.m. – 7 p.m. CT, Monday – Friday and 7 a.m. – 3 p.m. CT, Saturday. These drugs and supplies are part of your Medicare prescription drug coverage.1 Breast cancer preventive medications PEG-3350/NaCl/Na Bicarbonate/KCl TriLyte Anastrozole Exemestane Certain diabetic supplies for the Raloxifene administration of insulin Tamoxifen Insulin Syringes & Pen Needles Certain cholesterol-lowering medications Shingles vaccine Atorvastatin 10mg & 20mg Tablet Shingrix Lovastatin 10mg, 20mg & 40mg Tablet Zostavax Simvastatin 5mg, 10mg, 20mg & 40mg Tablet Tobacco cessation medications Certain colon prep products Buproban 150mg GaviLyte-C Chantix GaviLyte-G Nicotrol Inhaler PEG-3350/Electrolytes Nicotrol Nasal Spray Y0066_200527_081500_C Lower-cost non-Medicare over-the-counter drugs These drugs are covered in addition to the drugs in your plan’s drug list (formulary).2 Your plan covers these over-the-counter drugs at a $0 copay. Certain colon preparation products Tobacco cessation medications Bisacodyl Tablets Nicotine Gum Magnesium Citrate Solution Nicotine Lozenges Polyethylene Glycol Powder Nicotine Patches 1Information about the appeals and grievance process for these prescription drugs and supplies can be found in your Evidence of Coverage.
    [Show full text]
  • Tenncare Preferred Drug List (PDL)
    TennCare Preferred Drug List (PDL) Effective October 1, 2021 PA – Prior Authorization required, subject to specific PA criteria; QL – Quantity Limit (PA & NP agents require a PA before dispensing); B – Budgetary Reduction edit for utilization control (Standard NP PA criteria does not apply); ID – Class PA for patients with Intellectual or Developmental Disability Please note the following: • All agents must be prescribed by a provider with a Tennessee Medicaid Provider ID • Approval of NP agents requires trial and failure, contraindication, or intolerance of 2 preferred agents, unless otherwise indicated • With the exception of the “Branded Drugs Classified as Generics” list, TennCare is a mandatory generic program in accordance with state law (TCA 53-10-205). Approval of a branded product when a generic is available requires documentation of a serious adverse reaction from the generic via an FDA MedWatch form OR contraindication to an inactive ingredient in the AB-rated generic equivalent. Therapeutic Failure of an AB-rated generic equivalent may be considered for approval of branded products in the following high-risk medication classes: Anticonvulsants, Atypical Antipsychotics, HIV antivirals, Immunosuppressants, and Oncology Agents. • Unless otherwise noted, all agents listed on the PDL are referencing legend drugs which are prescription-required agents. Coverage of Over-the Counter (OTC) Products is listed at: https://www.optumrx.com/content/dam/openenrollment/pdfs/Tenncare/presciber/program-information/Covered%20OTC%20List.pdf Preferred
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al
    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
    [Show full text]
  • Early Refill Drug Utilization Review Drugs
    Early Refill Drug Utilization Review Drugs Published: 05/01/2012 Point-of-Sale Drug Authorization and Policy Drug Name Effective Date Override Override Center Override Acarbose X 11/8/2008 Acebutolol hydrochloride X 11/8/2008 acetaminophen X 11/8/2008 acetazolamide X 11/8/2008 acetazolamide sodium X 11/8/2008 acetylcholine X 11/8/2008 acetylcysteine X 11/8/2008 Acitretin X 11/8/2008 Acrivastine X 11/8/2008 activated charcoal X 11/8/2008 adalimumab X 11/8/2008 Adapalene X 11/8/2008 Adenosine X 11/8/2008 albumin human X 11/8/2008 Albuterol X 11/8/2008 albuterol sulfate X 11/8/2008 alclometasone dipropionate X 11/8/2008 aldesleukin X 11/8/2008 alendronate sodium X 11/8/2008 alfentanil hydrochloride X 11/8/2008 aliskiren hemifumarate X 11/8/2008 Alitretinoin X 11/8/2008 almotriptan malate X 11/8/2008 alosetron hydrochloride X 11/8/2008 Alprazolam X 1/6/2010 Aluminum X 11/8/2008 aluminum sulfate X 11/8/2008 amantadine hydrochloride X 11/8/2008 amcinonide X 11/8/2008 amino acids X 11/8/2008 aminophylline X 11/8/2008 amiodarone hydrochloride X 11/8/2008 amitriptyline hydrochloride X 11/8/2008 amlodipine besylate X 11/8/2008 Ammonium X 11/8/2008 Ammonium chloride X 11/8/2008 amobarbital X 1/6/2010 Point-of-Sale Drug Authorization and Policy Drug Name Effective Date Override Override Center Override Amoxicillin trihydrate X 11/8/2008 amphetamine X 1/6/2010 amyl nitrite X 11/8/2008 Amylase X 11/8/2008 apraclonidine hydrochloride X 11/8/2008 arformoterol tartrate X 11/8/2008 Arginine X 11/8/2008 arginine hydrochloride X 11/8/2008 aripiprazole X
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Wo 2010/118291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 14 October 2010 (14.10.2010) WO 2010/118291 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07C 229/54 (2006.01) A61K 31/136 (2006.01) kind of national protection available): AE, AG, AL, AM, C07C 229/38 (2006.01) A61P 13/12 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 10/030488 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 9 April 2010 (09.04.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/168,248 10 April 2009 (10.04.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AUS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated July 30, 2020 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Notice of Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List • Additions to category 1: Betahistine Hydrochloride L-Proline Citrulline Papaverine Hydrochloride* Copper Gluconate Phosphatidylcholine Diiodohydroxyquinoline Podophyllum Resin Glucosamine Sulfate Potassium Chloride Sodium Molybdate Glucosamine Sulfate Sodium Chloride Sodium Nitroprusside Hydrochloric Acid* Sodium Selenite/Sodium Selenite Pentahydrate* Ibutamoren Mesylate Trichloroacetic Acid* L-Citrulline* Ubidecarenone (Coenzyme Q10)* L-Lysine * Bulk drug substance is currently in Category 3 and is being moved to Category 1. • Minor revision to entry in Category 1 to correct a misspelling: o Correct the misspelling of “cimatidine” to “cimetidine” 1 Updated July 30, 2020 503B Category 1: Bulk Drug Substances Under Evaluation • 5-Methyltetrahydrofolate Calcium • Chromic Chloride • 17-alpha-Hydroxyprogesterone • Chromium chloride/ Chromium Chloride • Acetylcysteine Hexahydrate • Acyclovir • Ciclopirox Oleate • Adapalene • Cimetidine • Adenosine • Ciprofloxacin HCl • Allantoin • Citric Acid Anhydrous • Alpha Lipoic Acid • Citrulline/L-Citrulline • Alprostadil • Clindamycin Phosphate
    [Show full text]
  • Paramount Advantage™ Preferred Drug List
    Paramount Advantage™ Preferred Drug List (11/01/2019) INTRODUCTION ........................................................................................................................................................................................................................4 NOTICE OF NONDISCRIMINATION AND ACCESSIBILITY: DISCRIMINATION IS AGAINST THE LAW ............................................................................ 4 HOW TO SEARCH THIS DOCUMENT ...................................................................................................................................................................................... 6 PREFACE ...................................................................................................................................................................................................................................6 PHARMACY AND THERAPEUTICS COMMITTEE .................................................................................................................................................................. 6 DRUG LIST PRODUCT DESCRIPTIONS.................................................................................................................................................................................. 6 GENERIC SUBSTITUTION ........................................................................................................................................................................................................ 6 PLAN DESIGN ...........................................................................................................................................................................................................................7
    [Show full text]
  • Each Capsule Contains: Methenamine
    Pregnancy/Reproduction - Hyoscyamine and methenamine cross the placenta. Studies concerning the effect of hyoscyamine and methenamine on pregnancy and reproduction have not been done in animals or humans. Thus it is not known whether Uribel capsules cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Uribel capsules should be given to a pregnant woman only if clearly needed. Breastfeeding - Problems in humans have not been documented; however, methenamine and traces of hyoscyamine are excreted in breast milk. Accordingly, Uribel capsules should be given to a nursing mother with caution and only if clearly needed. Prolonged use - There have been no studies to establish the safety of prolonged use in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential. Rx Only Pediatric use - Infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids. DESCRIPTION: Uribel® capsules for oral administration. Geriatric use - Use with caution in elderly patients as they may respond to usual doses of hyoscyamine with excitement, agitation, drowsiness or confusion. Each capsule contains: ADVERSE REACTIONS: Methenamine ....................................................................................... 118 mg Cardiovascular: rapid heartbeat, flushing Sodium Phosphate Monobasic ............................................................. 40.8 mg Central Nervous System: blurred vision, dizziness, drowsiness Genitourinary: difficult micturition,
    [Show full text]
  • Miochol-E (Acetylcholine Chloride) Dose, Indications, Adverse Effects, Interactions
    Miochol-E (acetylcholine chloride) dose, indications, adverse effects, interactions... from PDR.net 5/8/18 18:45 print Close window CLASSES Parasympathomimetic Ophthalmological Surgical Aids DEA CLASS Rx DESCRIPTION Direct-acting parasympathomimetic ophthalmic agent; naturally-occurring neurohormone that mediates nerve impulse transmission at cholinergic sites. Used intraocularly to produce rapid miosis during ophthalmic surgery. COMMON BRAND NAMES Miochol-E HOW SUPPLIED Miochol-E Intraocular Inj Pwd F/Sol: 20mg DOSAGE & INDICATIONS For miosis induction in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment ocular surgery where rapid miosis may be required. Intraocular dosage (Miochol-E 1% solution) Adults In most cases, 0.5 to 2 mL of the 1% intraocular solution instilled into the anterior chamber produces satisfactory miosis. Intraocular irrigation with the drug must be gentle. Note that the syringe filter supplied with Miochol-E has a priming volume of 0.6 mL (approximately). For prolonged miosis, a second application may be used. MAXIMUM DOSAGE Adults 20 mg (2 mL of 1% Miochol-E solution) intraocularly per eye is usually sufficient. A second application may be needed for prolonged miosis. Geriatric 20 mg (2 mL of 1% Miochol-E solution) intraocularly per eye is usually sufficient. A second application may be needed for prolonged miosis. Adolescents Safety and efficacy have not been established. Children Safety and efficacy have not been established. Infants Safety and efficacy have not been established. Neonates Safety and efficacy have not been established. DOSING CONSIDERATIONS Hepatic Impairment No dosage adjustments are needed for intraocular use. Renal Impairment No dosage adjustments are needed for intraocular use.
    [Show full text]
  • Pharmaceutical Management and Formulary Manual (Pdf)
    PHARMACEUTICAL MANAGEMENT and FORMULARY MANUAL Approved by: The Chief Medical Officer Washington State Department of Corrections Note: Appendices II – Formulary Drug Listings and IV – Alternate Choices for Non-formulary Medications may be updated frequently as clinical data or contract prices change. Page 1 of 170 Formulary 600-HA002 Washington Department of Corrections (December 2019) DOC Formulary Table of Contents Definitions.......................................................................................................................... 5 Definitions...................................................................................................................... 5 Section I.............................................................................................................................. 7 Purpose ........................................................................................................................... 7 Section II ............................................................................................................................ 8 Promulgation of Policy ................................................................................................. 8 Section III ........................................................................................................................... 9 Voting Members ............................................................................................................ 9 Section IV ........................................................................................................................
    [Show full text]